Why MCAS Doesn’t Improve Until You Address the Gut | ROOT Method™ Melbourne

Domenic Pisanelli, BHSc Naturopathy | ATMS Registered | Vital Health & Natural Medicine, Melbourne | Updated July 2026

25+ Years Clinical Experience · Gut Health, Autoimmune Conditions, MCAS, Chronic Fatigue

The turning point for this patient was comprehensive stool testing that revealed hydrogen-dominant SIBO, severe dysbiosis, and depleted beneficial bacteria. Once we addressed the gut drivers alongside her mast cell stabilisation protocol, her symptoms didn't just improve. They finally made sense.

This is the pattern I see consistently. Most MCAS treatment fails not because the treatment is wrong, but because it ignores the gut. Mast cells don't activate randomly. They are immune sentinels responding to triggers. For many people with MCAS, those triggers come from the gastrointestinal tract. Until we find and address what is driving mast cell reactivity in the gut, we are managing symptoms. We are not treating the cause.

Understanding MCAS: More Than Histamine

Mast Cell Activation Syndrome is a condition where mast cells: immune cells that release histamine and other inflammatory mediators: become inappropriately activated in response to triggers that wouldn't normally cause such a reaction. For many people, MCAS is one of the most confusing and difficult conditions to manage, partly because of how unpredictably it presents.

The defining feature of MCAS is that symptoms don't stay in one place. They move across body systems.

Standard treatment: H1 and H2 antihistamines, mast cell stabilisers, a low-histamine diet: helps a lot of people manage day-to-day. The problem is that many patients reach a ceiling. They control the worst reactions but still live with persistent reactivity, a growing list of trigger foods, and an immune system that never fully settles. The reason, in most cases, is that the treatment is downstream of the actual problem.

The Gut-MCAS Connection

The gut contains the largest population of mast cells in the entire body. This is not a coincidence. The gut is where we encounter the external environment in the most direct way possible: through food, bacteria, pathogens, and everything that comes with them. Mast cells line the gut wall as sentinels, positioned to respond fast to threats.

When the gut environment becomes compromised, mast cells activate. Three pathways are most clinically relevant.

1. Intestinal permeability

When tight junctions between intestinal cells break down, bacterial endotoxins, undigested food proteins, and microbial fragments cross into circulation. Mast cells recognise these as threats and degranulate: releasing histamine, tryptase, and inflammatory cytokines. Over time this creates a feedback loop: permeability triggers mast cell activation, which damages the barrier further, which increases permeability.

Reference: Vicario M et al. Gut 2015;64(9):1379-88. Increased humoral immunity in IBS-D.

2. Histamine-producing dysbiosis

Certain gut bacteria: including Klebsiella, Proteus, and some strains of E. coli: produce histamine directly by converting the amino acid histidine. When these species overgrow, or when beneficial bacteria that help clear histamine are depleted, the gut becomes a histamine factory. Systemic histamine burden rises even without high-histamine dietary intake.

In clinical practice, I see this pattern regularly. A patient improves on a strict low-histamine diet, then plateaus. Adding moderate-histamine foods immediately triggers a reaction. The diet is masking the driver, not fixing it. When we correct the dysbiosis, many patients find they can eat foods they had restricted for years.

Reference: Maintz L, Novak N. Am J Clin Nutr 2007;85(5):1185-96. Histamine and histamine intolerance.

3. SIBO and fungal overgrowth (SIFO)

SIBO occurs when bacteria migrate into the small intestine and proliferate where they shouldn't be. SIFO involves fungal overgrowth, most often Candida. Both increase intestinal permeability, raise systemic histamine and biogenic amine levels, and amplify immune activation. Treating SIBO or SIFO often stabilises MCAS symptoms that were unresponsive to antihistamines alone.

Clinical Patterns: When to Suspect Gut-Driven MCAS

Not all MCAS is primarily gut-driven. But certain patterns make gut involvement likely. The cards below lay out the three most common presentations I see in clinic.

Why Standard MCAS Treatment Falls Short

Antihistamines, mast cell stabilisers, and dietary restriction address downstream mediators. They don't address what the mast cells are reacting to. Each intervention has a real limitation.

• Antihistamines block receptors, not triggers. H1 and H2 blockers reduce symptoms by preventing histamine from binding. They do not stop mast cells from degranulating, and they do not address why histamine is being released in the first place.
• Low-histamine diets provide relief but do not restore tolerance. Strict histamine restriction is a useful tool during the stabilisation phase. Maintained indefinitely without treating root causes, it can reduce microbiome diversity and create nutritional deficiencies. The goal is food reintroduction, not permanent restriction.
• Mast cell stabilisers help but do not fix the gut. Quercetin, cromolyn, and ketotifen reduce mast cell degranulation. If intestinal permeability, dysbiosis, or SIBO persist, mast cells will keep encountering activating triggers regardless.

The ROOT Method for Gut-Driven MCAS

ROOT stands for Review, Order, Observe, Treat. It's a systematic four-phase framework I developed over 25 years of clinical practice for working through complex, multi-system conditions. For MCAS patients, the sequence matters as much as the interventions themselves.

Testing: What We Actually Measure

Standard pathology panels don't assess gut-MCAS drivers. The following functional tests are what change the clinical picture.

Treatment: Sequencing Matters

MCAS patients are often highly sensitive to treatment. Aggressive gut-clearing protocols without first stabilising mast cell reactivity reliably produce severe reactions and often cause patients to stop treatment entirely. The right order makes the difference between a protocol that works and one that gets abandoned.

Step 1: Stabilise mast cells

Before treating any gut infection or overgrowth, we reduce baseline reactivity. Quercetin (500 to 1,000mg, two to three times daily) has the best evidence for mast cell stabilisation among natural compounds. Vitamin C supports histamine breakdown. DAO enzyme supplementation helps where genetic DAO insufficiency is present. Spore-based probiotics: Bacillus species: are generally better tolerated in MCAS than standard Lactobacillus strains, which include histamine-producing species.

Reference: Weng Z et al. PLoS One 2012;7(3):e33805. Quercetin vs cromolyn for mast cell cytokine release.

Step 2: Treat the gut driver

Treatment is specific to what testing found. For hydrogen-dominant SIBO: herbal antimicrobials (berberine, oregano oil, allicin) or prescription rifaximin where appropriate, alongside prokinetic support to restore migrating motor complex function. For fungal overgrowth: antifungal botanicals with biofilm disruption support. For histamine-producing dysbiosis: targeted antimicrobials against the specific species identified, with careful prebiotic reintroduction once cleared.

Step 3: Repair the gut barrier

With overgrowth addressed, we rebuild the lining. L-glutamine (5 to 15g daily) provides fuel for enterocytes. Zinc carnosine (75 to 150mg daily) has direct human evidence for mucosal healing and tight junction restoration. Omega-3 fatty acids (2 to 4g EPA+DHA) reduce gut mucosal inflammation. Butyrate supports colonocyte health. Collagen peptides provide the structural amino acids needed for gut lining repair.

Reference: Mahmood A et al. Gut 2007;56(2):168-75. Zinc carnosine for small bowel integrity.

Step 4: Gradual food reintroduction

Once gut drivers are treated and barrier function is improving, we begin systematic reintroduction. One food at a time. Moderate-histamine foods before high-histamine. Minimum three to four days between new foods to catch delayed reactions. The goal is expanding dietary variety, not maintaining restriction indefinitely. Most patients who complete the full protocol find they can reintroduce foods they'd avoided for years.

The vagus nerve: the piece most protocols miss

The vagus nerve is the primary communication pathway between gut and brain. When vagal tone is low: which it often is in people with chronic stress, trauma history, or dysautonomia: the gut immune system becomes dysregulated and mast cell reactivity increases. Simple vagal toning practices (humming, gargling, cold water face immersion, coherent breathing at five to six breaths per minute) have a measurable effect on gut immunity and mast cell behaviour. These are not alternative interventions. They are supported by evidence on gut-brain-immune communication and are one of the most underutilised tools in MCAS management.

Reference: Bonaz B et al. Front Neurosci 2018;12:49. The vagus nerve and the gut-brain axis.

What Recovery Actually Looks Like

Recovery from gut-driven MCAS is not linear. Most people describe it as waves. Things improve, then a flare hits, and it feels like going backward. That is part of the process, not evidence that the protocol isn't working. Understanding the general trajectory helps.

What Patients Say

Frequently Asked Questions